Abstract
Amyloid β (Aβ) polypeptide plays a key role in determining the state of protein aggregation in Alzheimer’s disease. The hydrophobic C-terminal part of the Aβ peptide is critical in triggering the transformation from α-helical to β- sheet structure. We hypothesized that phospholipase A2 (PLA2) may inhibit the aggregation of Aβ peptide by interacting with the peptide and keeping the two peptide chains apart. In order to examine the nature of interactions between PLA2 and Aβ peptide, we prepared and crystallized complex of Naja naja sagittifera PLA2 with the C-terminal hepta-peptide Val-Gly-Gly-Val-Val-Ile-Ala. The X-ray intensity data were collected to 2.04 A resolution and the structure was determined by molecular replacement and refined to the crystallographic R factor of 0.186. The structural analysis revealed that the peptide binds to PLA2 at the hydrophobic substrate binding cavity forming at least eight hydrogen bonds and approximately a two dozen Van der Waals interactions. The number and nature of interactions indicate that the affinity between PLA2 and the hepta-peptide is greater than the affinity between two Aβ peptide chains. Therefore, PLA2 is proposed as a probable ligand to prevent the aggregation of Aβ peptides.
Keywords: Alzheimer's disease, Aβ peptide, C-terminus, co-crystallization, phospholipase A2, VGGVVIA.
CNS & Neurological Disorders - Drug Targets
Title:Protein Interactions Between the C-Terminus of Aβ-Peptide and Phospholipase A2 - A Structure Biology Based Approach to Identify Novel Alzheimer's Therapeutics
Volume: 13 Issue: 7
Author(s): Zeenat Mirza, Vikram G. Pillai and Mohammad A. Kamal
Affiliation:
Keywords: Alzheimer's disease, Aβ peptide, C-terminus, co-crystallization, phospholipase A2, VGGVVIA.
Abstract: Amyloid β (Aβ) polypeptide plays a key role in determining the state of protein aggregation in Alzheimer’s disease. The hydrophobic C-terminal part of the Aβ peptide is critical in triggering the transformation from α-helical to β- sheet structure. We hypothesized that phospholipase A2 (PLA2) may inhibit the aggregation of Aβ peptide by interacting with the peptide and keeping the two peptide chains apart. In order to examine the nature of interactions between PLA2 and Aβ peptide, we prepared and crystallized complex of Naja naja sagittifera PLA2 with the C-terminal hepta-peptide Val-Gly-Gly-Val-Val-Ile-Ala. The X-ray intensity data were collected to 2.04 A resolution and the structure was determined by molecular replacement and refined to the crystallographic R factor of 0.186. The structural analysis revealed that the peptide binds to PLA2 at the hydrophobic substrate binding cavity forming at least eight hydrogen bonds and approximately a two dozen Van der Waals interactions. The number and nature of interactions indicate that the affinity between PLA2 and the hepta-peptide is greater than the affinity between two Aβ peptide chains. Therefore, PLA2 is proposed as a probable ligand to prevent the aggregation of Aβ peptides.
Export Options
About this article
Cite this article as:
Mirza Zeenat, Pillai G. Vikram and Kamal A. Mohammad, Protein Interactions Between the C-Terminus of Aβ-Peptide and Phospholipase A2 - A Structure Biology Based Approach to Identify Novel Alzheimer's Therapeutics, CNS & Neurological Disorders - Drug Targets 2014; 13 (7) . https://dx.doi.org/10.2174/1871527313666140917112248
DOI https://dx.doi.org/10.2174/1871527313666140917112248 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Potential of Phosphodiesterase Inhibitors for Endothelial Dysfunction- Related Diseases
Current Pharmaceutical Design MicroRNAs in Peripheral Artery Disease
Current Topics in Medicinal Chemistry Anti-Inflammatory, Gastrointestinal and Hepatoprotective Effects of Ocimum sanctum Linn: An Ancient Remedy with New Application
Inflammation & Allergy - Drug Targets (Discontinued) In Vitro and In Vivo Profiles and Characterization of Insulin Nanocarriers Based in Flexible Liposomes Designed for Oral Administration
Letters in Drug Design & Discovery Fighting Alzheimer's Disease and Type 2 Diabetes: Pathological links and Treatment Strategies
CNS & Neurological Disorders - Drug Targets Circulating Meteorin-like Levels in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis
Current Pharmaceutical Design Cognitive Function and Heart Failure: The Role of the Adrenergic System
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cardiovascular Risk in Patients with Primary Hyperparathyroidism
Current Pharmaceutical Design Comparison Between the Effects of Bupivacaine and Levobupivacaine for Spinal Anesthesia on QT Dispersion
Cardiovascular & Hematological Disorders-Drug Targets Structure and Function of Poly(ADP-ribose) Polymerase-1: Role in Oxidative Stress-Related Pathologies
Current Vascular Pharmacology New Drugs for Immune Targeting
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Treatment of Leishmaniasis: A Review and Assessment of Recent Research
Current Pharmaceutical Design Subject Index To Volume 6
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot Topic: Novel Peptides and Proteins in Diabetes Mellitus (Guest Editors: Po Sing Leung and Marc de Gasparo)]
Current Protein & Peptide Science The Central Nervous System as a Promising Target to Treat Diabetes Mellitus
Current Topics in Medicinal Chemistry Molecular Concept of Diabetic Wound Healing: Effective Role of Herbal Remedies
Mini-Reviews in Medicinal Chemistry Identification of Phenolic Compounds from Nettle as New Candidate Inhibitors of Main Enzymes Responsible on Type-II Diabetes
Current Drug Discovery Technologies Factors Affecting Residual Platelet Aggregation in Prasugrel Treated Patients
Current Pharmaceutical Design Immunoglobulin Free Light Chains in Immune Responses
Current Immunology Reviews (Discontinued) The Role of T and B Cells in Atherosclerosis: Potential Clinical Implications
Current Pharmaceutical Design